Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 2
2004 2
2005 2
2010 1
2012 4
2013 3
2014 1
2015 1
2016 3
2018 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
Groenendaal-van de Meent D, den Adel M, Kerbusch V, van Dijk J, Shibata T, Kato K, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Clin Pharmacol Drug Dev. 2022 Apr;11(4):486-501. doi: 10.1002/cpdd.1076. Epub 2022 Feb 19. Clin Pharmacol Drug Dev. 2022. PMID: 35182045 Free PMC article. Clinical Trial.
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M. Dickinson J, et al. Among authors: schaddelee m. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3. Clin Drug Investig. 2013. PMID: 23208320 Clinical Trial.
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, den Adel M, van Dijk J, Golor G, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Clin Ther. 2021 Jun;43(6):1079-1091. doi: 10.1016/j.clinthera.2021.03.025. Epub 2021 May 5. Clin Ther. 2021. PMID: 33962762 Free article. Clinical Trial.
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Groenendaal-van de Meent D, den Adel M, van Dijk J, Barroso-Fernandez B, El Galta R, Golor G, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):685-692. doi: 10.1007/s13318-018-0480-z. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29752643 Free PMC article. Clinical Trial.
Purines in portugal.
Stone TW, Zimmermann H, Lopes LV, Schaddelee MP. Stone TW, et al. Among authors: schaddelee mp. Trends Neurosci. 2001 Nov;24(11):629-30. doi: 10.1016/s0166-2236(00)01992-5. Trends Neurosci. 2001. PMID: 11672788 No abstract available.
D optimal designs for three Poisson dose-response models.
Maloney A, Simonsson US, Schaddelee M. Maloney A, et al. Among authors: schaddelee m. J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):201-11. doi: 10.1007/s10928-013-9300-x. Epub 2013 Feb 19. J Pharmacokinet Pharmacodyn. 2013. PMID: 23420229
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
de Greef-van der Sandt I, Newgreen D, Schaddelee M, Dorrepaal C, Martina R, Ridder A, van Maanen R. de Greef-van der Sandt I, et al. Among authors: schaddelee m. Clin Pharmacol Ther. 2016 Apr;99(4):442-51. doi: 10.1002/cpt.271. Epub 2015 Nov 13. Clin Pharmacol Ther. 2016. PMID: 26422298 Clinical Trial.
An example of optimal phase II design for exposure response modelling.
Maloney A, Schaddelee M, Freijer J, Krauwinkel W, van Gelderen M, Jacqmin P, Simonsson US. Maloney A, et al. Among authors: schaddelee m. J Pharmacokinet Pharmacodyn. 2010 Oct;37(5):475-91. doi: 10.1007/s10928-010-9168-y. Epub 2010 Sep 25. J Pharmacokinet Pharmacodyn. 2010. PMID: 20872056
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T. Eltink C, et al. Among authors: schaddelee m. Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782. Int J Clin Pharmacol Ther. 2012. PMID: 22943933 Clinical Trial.
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. Krauwinkel W, et al. Among authors: schaddelee m. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1. Eur J Drug Metab Pharmacokinet. 2014. PMID: 23728524 Clinical Trial.
21 results